CEOP/IVE/GDP Alternating Regimen Compared with CEOP as the First-line Therapy for Newly Diagnosed Patients with Peripheral T-cell Lymphoma: Results from a Phase 2, Multi-center, Randomized, Controlled Clinical Trial

Name: CEOP/IVE/GDP Alternating Regimen Compared with CEOP as the First-line Therapy for Newly Diagnosed Patients with Peripheral T-cell Lymphoma: Results from a Phase 2, Multi-center, Randomized, Controlled Clinical Trial
Creator: Weili Zhao
Published: 2020-04-06T03:30:51.515Z
Keywords: Exome Sequencing

Zhao, Weili

doi:10.17632/jcp3kc4tzx.1

CEOP/IVE/GDP Alternating Regimen Compared with CEOP as the First-line Therapy for Newly Diagnosed Patients with Peripheral T-cell Lymphoma: Results from a Phase 2, Multi-center, Randomized, Controlled Clinical Trial

Published: 6 April 2020| Version 1 | DOI: 10.17632/jcp3kc4tzx.1

Contributor:

Weili Zhao

Description

Given the poor response to CHOP-based regimens and the potential anti-lymphoma activity by alternating chemotherapy in PTCL, we conducted a phase 2, multi-center, randomized, controlled trial, comparing the efficacy and safety of CEOP/IVE/GDP alternating regimen with CEOP in a Chinese cohort of newly diagnosed patients with PTCL.

CEOP/IVE/GDP Alternating Regimen Compared with CEOP as the First-line Therapy for Newly Diagnosed Patients with Peripheral T-cell Lymphoma: Results from a Phase 2, Multi-center, Randomized, Controlled Clinical Trial

Description

Files

Categories

Licence